
Transannular Reductive Rearrangement of α -Amino Ketones: Construction of Aza-tricyclic Frameworks of Several Alkaloids

Jian Zhang,[†] Yong-Qiang Wang,[†] Xin-Wei Wang,[†] and Wei-Dong Z. Li^{*,†,‡}

[†]State Key Laboratory of Applied Organic Chemistry, Lanzhou University, Lanzhou 730000, P. R. China [‡]Innovative Drug Research Centre, Chongqing University, Chongqing 401331, P. R. China

Supporting Information

ABSTRACT: Transannular reductive rearrangement of bridged cyclic α -amino ketones led to the aza-tricyclic frameworks azepinoindole, hydrolulolidine, and hydrojulolidine of the typical alkaloids of *Stemona, Aspidosperma,* and *Lycopodium,* respectively. This facile approach demonstrates the potential applicability of the Clemmensen–Clemo–Prelog–Leonard reductive rearrangement of tricyclic α -amino ketones for the aza-heterocycle synthesis.



INTRODUCTION

During our previous studies on the total synthesis of *Cephalotaxus* alkaloids,¹ two crucial reductive rearrangement reactions $(1 \rightarrow 2 \text{ and } 3 \rightarrow 4;$ Figure 1) were designated for the construction of the benzazepine core ring system of cephalotaxine. Those facile and effective transformations were devised on the basis of an interesting Clemmensen reductive rearrangement $(5 \rightarrow 7;$ Figure 2) of a cyclic α -amino ketone 5, which is in marked contrast with the complementary Wolff–




Figure 1. Previous synthesis of benzazepine core of cephalotaxine.^{1a}




Figure 2. Clemmensen-Clemo-Prelog-Leonard reductive rearrangement.

Kishner reduction of carbonyl (5 \rightarrow 6; Figure 2), first discovered by Clemo² and later verified by Prelog.³ Subsequent systematic studies by Leonard⁴ and co-workers suggested a probable mechanistic pathway involving the reductive rupture of the C–N bond, transannular formation of iminium intermediate 5a, and subsequent reduction of 5a as illustrated

 Received:
 April 17, 2013

 Published:
 May 31, 2013

in Figure 2 (path a). An alternative mechanistic pathway (path b, Figure 2) via the rearrangement of the zinc carbenoid intermediate **5b** to **5c** might be suggested on the basis of recent studies on the classic Clemmensen reduction.^{41-n,o}

In seeking the general applicability of the so-named Clemmensen–Clemo–Prelog–Leonard reductive rearrangement⁵ for the construction of the aza-tricyclic frameworks (i.e., azepinoindole, hydrolulolidine, and hydrojulolidine; Figure 3a-c) of some typical alkaloids of *Stemona*,⁶




Figure 3. Typical aza-tricyclic frameworks of alkaloids.

Aspidosperma,⁷ and Lycopodium,⁸ we set out to explore a transannular reductive rearrangement approach $(9 \rightarrow 10;$ Figure 4) of a series of bridged cyclic α -amino ketones. This report details the experimental results of these studies.




Figure 4. Transannular Clemmensen reductive rearrangement approach.

RESULTS AND DISCUSSION

As shown in Scheme 1, allylation of diester $11^{2a,9}$ afforded piperidine derivative 12, which was cyclized via Dieckmann condensation to give predominately bicyclic ester 13 as the enol form. Further carbocyclization of 13 was achieved via a Mn^{III}mediated oxidative radical process¹⁰ to give the bridged cyclic α -amino ketone 14 in good yield. Hydrogenation of 14 afforded the desired bridged cyclic α -amino ketone 15, which was subjected to the classic Clemmensen reduction conditions.⁴ Tricyclic amine 16 was isolated as the sole reaction product in 75% yield, and its skeletal structure and stereostructure were determined by X-ray crystallography as shown (see Supporting Information for details). It is intriguing to note that the all-*trans* ring-fused azepinoindole derivative **16** is the only diastereomer produced.¹¹

Encouraged by the initial case study, we next examined the reactivity of tricyclic α -amino ketone 21, which was synthesized through an analogous reaction sequence (via 18 and 19) as outlined in Scheme 2, from the readily available proline derivative 17.9b,12 When the analogous experimental protocol for the conversion of $13 \rightarrow 14$ was applied to the allyl ester 19, only trace amounts of the desired bridged carbocyclization product analogous to 14 were detected. Bromination of 19 with NBS gave a mixture of diastereomeric bromide 20 in excellent yield. The bridged carbocyclization of 20 was achieved via a reductive radical pathway to afford the desired tricyclic α -amino ketone 21 in 50% yield.¹³ Reductive rearrangement of 21 under the typical Clemmensen reduction conditions furnished the sole hydrolulolidine derivative 22 in 45% yield, which interestingly is an all-cis fused aza-tricycle whose stereostructure was established according to the studies detailed in Scheme 5 below.

As we initially planned, diester 23^{4d} was transformed smoothly into the allylated benzazepinone derivative 25 via β -ketoester 24. However, all attempts, including the Mn^{III}mediated oxidative cyclization and the reductive radical cyclization of the corresponding α -keto bromide, for the bridged cyclic ring closure of 25 failed. After considerable experimentation, we found that the desired tricyclic α -amino ketone derivatives 26a and 26b (5.5:1) could be readily prepared from β -ketoester 24 via the annulation with acrolein mediated by DBU followed by immediate acetylation. This tandem Michael–Aldolization approach¹⁴ provides an efficient alternative synthesis for compounds bearing an acetoxy group on the bridge.


Interestingly, both diastereomers 26a and 26b underwent smooth transannular rearrangement under much milder reductive conditions (Zn/HOAc) even at ambient temperature (Scheme 3). The hydrojulolidine derivatives 27a and 27b were isolated in excellent yield in a ratio of 65:25. Notably, the olefin function was introduced in the fused tricyclic ring system. The structure of 27a was confirmed by the X-ray crystallographic analysis of the diol derivative 28. Diastereomeric hydrojulolidine derivative 27b underwent facile lactonization under acidic conditions, leading to crystalline lactone 29.

As outlined in Scheme 4, the major reductive rearrangement product 27a was readily converted further into the hydrojulolidone 33 through a reaction sequence, which included (1) regioselective hydroxylation of olefin, (2) alcohol oxidation, (3) dehydrogenative oxidation, and (4) decarboxylation.¹⁵ Hydrojulolidone 33 is a known advanced intermediate¹⁴ for the synthesis of *Lycopodium* alkaloids according to the pioneering research of Wiesner^{16a,b} and Snider^{17e,f} in this field.¹⁷

The above tandem Michael–Aldol annulation method was extended to the elaboration of other reductive rearrangement precursors. As shown in Scheme 5, bicyclic amine $35^{9b,12}$ was annulated with acrolein smoothly and then acetylated to give the anticipated tricyclic α -amino ketone derivatives **36a** and **36b** in good yield with a ratio of 4:1. Reductive rearrangement of either **36a** or **36b** mediated by zinc dust in glacial acetic acid under a reflux furnished the sole tricyclic amine **37** in 55–58% yield. Catalytic hydrogenation of **37** produced the sole saturated tricyclic amine **22**, which is identical spectroscopically with the aforementioned Clemmensen reductive rearrangement product of **21** (Scheme 2). The all-*cis* fused stereostructure for

Article





aza-tricycle **22** was deduced based on the fact that the dihydroxylation of **37** produced the all-*cis* fused tricyclic diol **38**, whose stereostructure was established via X-ray crystallographic analysis. It is worth noting that the attachment of an acetoxyl functional group not only facilitates the transannular reductive rearrangement but also results in the introduction of an olefin in the product ring structure for further functionalization.

CONCLUSION

We have demonstrated in this report that the bridged cyclic α amino ketones were effective substrates for the transannular Clemmensen reductive rearrangement, leading to a potentially applicable approach for the construction of various aza-tricyclic heterocycles. Readily accessible acetoxylated bridged cyclic precursors (**26** and **36**) via tandem Michael–Aldol annulation with acrolein exhibit peculiar reactivity worthy of further study. Development of this type of transannular rearrangement and further application of this method in aza-heterocycle synthesis are underway.

EXPERIMENTAL SECTION¹⁸


General. Commercially available reagents were used without further purification, unless otherwise stated. ¹H and ¹³C NMR spectra were taken on a 400 MHz spectrometer. Proton chemical shifts are reported in parts per million (δ) (CDCl₃, δ 7.27 or C₆D₆, δ 7.16), and carbon chemical shifts are reported in parts per million (δ) (CDCl₃, δ 7.27 or C₆D₆, δ 7.16), and carbon chemical shifts are reported in parts per million (δ) (CDCl₃, δ 7.27 or C₆D₆, δ 128.4). Infrared spectra were recorded on a FT-IR spectrometer and are reported in reciprocal centimeter (cm⁻¹). HRMS

were determined on a FT-ICR spectrometer. Melting points were measured on a hot stage and are uncorrected.


Ethyl 1-(4-Ethoxy-4-oxobutyl)piperidine-2-carboxylate $(11)^{2}$ Anhydrous potassium carbonate (345 mg, 2.50 mmol) at room temperature was added to a mixture of ethyl 4-bromobutanoate (195 mg, 1.00 mmol) and ethyl piperidine-2-carboxylate hydrochloride (194 mg, 1.00 mmol) in anhydrous acetonitrile (10 mL). The reaction mixture was heated to reflux for 10 h. After the reaction mixture was cooled to room temperature, 5 mL of H₂O was added. The combined organics were extracted with ethyl acetate $(2 \times 20 \text{ mL})$, washed with water and brine, and dried over anhydrous Na2SO4. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography eluting with petroleum ether/EtOAc (4:1) to give 11 as a colorless oil (260 mg, 96% yield). Compound 11: $R_f = 0.5$ (2:1 petroleum ether/EtOAc); IR (film) ν_{max} 2937, 1733, 1448, 1176, 1162, 1030; ¹H NMR (400 MHz, CDCl₃) δ 1.23-1.29 (m, 6H), 1.33–1.43 (m, 1H), 1.58–1.64 (m, 3H), 1.70–1.84 (m, 4H), 2.15-2.20 (m, 1H), 2.24-2.39 (m, 3H), 2.50-2.58 (m, 1H), 3.03-3.09 (m, 2H), 4.09–4.20 (m, 4H); 13 C NMR (100 MHz, CDCl₃) δ 14.1, 14.2, 22.0, 22.4, 25.2, 29.5, 32.0, 50.1, 55.5, 60.0, 60.1, 65.0, 173.4. 173.7.

Ethyl 2-Allyl-1-(4-ethoxy-4-oxobutyl)piperidine-2-carboxylate (12). Anhydrous potassium carbonate (345 mg, 2.50 mmol) at room temperature was added to a mixture of compound 11 (271 mg, 1.00 mmol) and allyl bromide (0.17 mL, 2.00 mmol) in anhydrous acetonitrile (10 mL). The reaction mixture was then brought to reflux. After refluxing for 12 h, the reaction mixture was cooled to rt, and the reaction was quenched with H_2O (5 mL). The resulting mixture was extracted with ethyl acetate (2 × 20 mL), and the combined organic extracts were washed with water and brine and dried over anhydrous Na₂SO₄. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography eluting with

Scheme 3




Scheme 4



10:1 petroleum ether/EtOAc to give compound **12** as a colorless oil (296 mg, 95% yield). Compound **12**: $R_f = 0.65$ (4:1 petroleum ether/EtOAc); IR (film) ν_{max} 2936, 1733, 1446, 1372, 1212, 1167, 1026; ¹H NMR (400 MHz, CDCl₃) δ 1.21–1.26 (m, 6H), 1.35–1.55 (m, 5H), 1.67–1.75 (m, 2H), 1.87–1.90 (m, 1H), 2.24–2.28 (m, 2H), 2.35–2.53 (m, 4H), 2.71–2.74 (m, 1H), 2.81–2.89 (m, 1H), 4.06–4.15 (m, 4H), 5.01–5.05 (m, 2H), 5.76–5.86 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 14.1, 14.4, 21.4, 24.1, 25.7, 31.9, 33.6, 40.7, 47.8, 49.9, 59.9, 60.1, 65.7, 117.5, 133.9, 173.9, 174.8; HRMS (ESI) *m/z* calcd for C₁₇H₃₀NO₄ 312.2172, found for [M + H]⁺ 312.2169.

Ethyl 9a-Allyl-9-hydroxy-2,3,4,6,7,9a-hexahydro-1H-quinolizine-8-carboxylate (13). A solution of compound 12 (311 mg, 1.00 mmol) in toluene (2 mL) was added to a refluxing mixture of KO^tBu (134 mg, 1.20 mmol) in 10 mL of dry toluene. After 45 min, the reaction mixture was cooled to rt and diluted with 20 mL of EtOAc. The mixture was washed with water and brine, dried, and evaporated Scheme 5



under reduced pressure. The residue was purified by silica gel column chromatography eluting with 8:1 petroleum ether/EtOAc to give compound 13 as a colorless oil (199 mg, 75% yield). Compound 13 (predominately as the enol form): $R_f = 0.20$ (2:1 petroleum ether/

EtOAc); IR (film) $\nu_{\rm max}$ 3074, 2936, 1727, 1650, 1283, 1226, 1137, 1036; $^{1}{\rm H}$ NMR (400 MHz, CDCl₃) δ 1.31 (t, 3H, J = 7.2 Hz), 1.43–1.48 (m, 2H), 1.56–1.65 (m, 3H), 1.88–1.95 (m, 1H), 2.14–2.20 (m, 1H), 2.44–2.63 (m, 3H), 2.65–2.87 (m, 3H), 3.03–3.09 (m, 1H), 4.19–4.25 (m, 2H), 5.04–5.09 (m, 2H), 5.82–5.92 (m, 1H), 12.45 (s, 1H, OH); $^{13}{\rm C}$ NMR (100 MHz, CDCl₃) δ 14.3, 20.6, 21.0, 23.9, 29.6, 39.3, 44.7, 48.9, 59.9, 60.4, 95.0, 116.8, 134.2, 172.8, 174.5; HRMS (ESI) m/z calcd for $\rm C_{15}H_{24}\rm NO_3$ 266.1753, found for $\rm [M + H]^+$ 266.1751.

Ethyl 12-Oxo-1,2,3,4,6,7,8,9-octahydro-8,11amethanopyrido[1,2-a]azocine-8-carboxylate (14). Powdered Mn(OAc)₃·2H₂O (536 mg, 2.00 mmol) at room temperature was added to a solution of compound 13 (265 mg, 1.00 mmol) in DMSO (10 mL). After the reaction mixture was stirred at room temperature for 4 h, EtOAc (40 mL) was added. The mixture was washed with water $(3 \times 10 \text{ mL})$ and brine and dried over anhydrous Na₂SO₄. After evaporation of the solvent, the residue was purified by silica gel column chromatography eluting with 20:1 petroleum ether/EtOAc to give compound 14 as a colorless oil (205 mg, 78% yield). Compound 14: $R_f = 0.4$ (4:1 petroleum ether/EtOAc); IR (film) ν_{max} 2940, 1736, 1721, 1639, 1256, 1143; ¹H NMR (400 MHz, CDCl₃) δ 1.27 (t, 3H, J = 7.2 Hz), 1.37-1.48 (m, 3H), 1.51-1.55 (m, 2H), 1.63-1.76 (m, 3H), 1.88-2.00 (m, 2H), 2.38-2.45 (m, 1H), 2.84-2.89 (m, 1H), 2.99-3.03 (m, 1H), 3.11-3.18 (m, 1H), 4.17-4.26 (m, 3H), 6.12 (d, J = 7.6 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 14.1, 17.7, 19.5, 25.7, 29.5, 36.2, 39.6, 46.9, 58.8, 61.1, 64.0, 89.9, 138.2, 171.8, 205.4; HRMS (ESI) m/z calcd for C₁₅H₂₂NO₃ 264.1594, found for $[M + H]^+$ 264.1600.

Ethyl 12-Oxodecahydro-8,11a-methanopyrido[1,2-a]**azocine-8-carboxylate (15).** A flask containing 14 (263 mg, 1.00 mmol) and 10% Pd/C (20 mg) in 5 mL of EtOH was thoroughly purged with hydrogen and was then fitted with a hydrogen balloon. After the mixture was stirred for 5 h at room temperature, it was filtered. The filtrate was concentrated under reduced pressure and to give compound 15 as a colorless oil (252 mg, 95% yield). Compound 15: $R_f = 0.20$ (EtOAc); IR (film) ν_{max} 2937, 1735, 1450, 1258, 1157, 1107, 1025; ¹H NMR (400 MHz, CDCl₃) δ 1.29 (t, 3H, J = 7.0 Hz), 1.37–1.43 (m, 2H), 1.49–1.59 (m, 4H), 1.63–1.67 (m, 1H), 1.73–1.77 (m, 1H), 1.94–1.99 (m, 1H), 2.04–2.14 (m, 2H), 2.61–2.73 (m, SH), 2.84–2.93 (m, 1H), 3.37 (td, 1H, J = 13.0, 4.2 Hz), 4.19–4.26 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 14.1, 19.6, 20.5, 25.6, 31.5, 32.5, 34.5, 35.4, 48.1, 50.2, 56.9, 61.2, 63.3, 172.2, 210.2; HRMS (ESI) m/z calcd for C₁₅H₂₄NO₃ 266.1751, found for [M + H]⁺ 266.1757.

(31S,7aS,10aS)-Ethyl Dodecahydroazepino[3,2,1-hi]indole-10a-carboxylate (16). Mossy zinc (5.20 g, 80.0 mmol) was amalgamated by being shaken with mercuric chloride (565 mg, 2.10 mmol), concentrated HCl (0.5 mL), and H₂O (8 mL) for 5 min. The resulting mixture was decanted from the amalgam and then washed once with distilled water. Compound 15 (1.06 g, 4.00 mmol) in 10 mL of concentrated HCl was added slowly to the above amalgam. The resulting mixture was heated under gentle reflux for 45 min and then cooled to room temperature, filtered, adjusted to pH 9-10 with saturated Na₂CO₃, and extracted with CHCl₃ (3 \times 30 mL). The combined organic layers were washed with water and brine, dried, and evaporated under reduced pressure. The residue was purified by silica gel column chromatography eluting with 40:1 CH2Cl2/CH3OH to give compound 16 as white solids (750 mg, 75% yield). Compound **16**: Mp 82–84 °C; $R_f = 0.45$ (10:1 CH₂Cl₂/MeOH); IR (film) ν_{max} 2931, 1726, 1451, 1177, 1027; ¹H NMR (400 MHz, C₆D₆) δ 0.83-0.87 (m, 2H), 0.97 (t, 3H, J = 7.2 Hz), 1.07 (td, 1H, J = 12.0, 4.0 Hz), 1.18-1.29 (m, 1H), 1.34-1.42 (m, 1H), 1.45-1.51 (m, 2H), 1.58-1.72 (m, 6H), 1.92–1.95 (m, 1H), 2.23–2.30 (m, 2H), 2.34–2.41 (m, 2H), 2.42-2.55 (m, 1H), 2.90-2.95 (m, 1H), 3.06-3.10 (m, 1H), 3.96–4.02 (m, 2H); ¹³C NMR (100 MHz, C_6D_6) δ 14.3, 23.5, 26.3, 28.3, 34.1, 34.2, 34.9, 35.6, 37.3, 53.3, 53.4, 53.7, 59.7, 79.9, 174.4; HRMS (ESI) m/z calcd for C₁₅H₂₆NO₂ 252.1958, found for [M + H]⁺ 252.1956. X-ray crystallographic data for 16: C15H25NO2, triclinic, space group $P\overline{1}$, a = 8.720(2) Å, b = 13.383(3) Å, c = 15.606(3) Å, $\alpha =$ $115.17(3)^{\circ}$, $\beta = 96.03(3)^{\circ}$, $\gamma = 98.19(3)^{\circ}$, Z = 5, $d_{\text{calcd}} = 1.488 \text{ g/cm}^3$, $R_1(I > 2\sigma(I)) = 0.0538, wR_2 = 0.1069.$

(S)-Ethyl 1-(4-Ethoxy-4-oxobutyl)pyrrolidine-2-carboxylate (17).^{9b,12} Compound 17 was prepared by a procedure analogous to that of compound 11 and gave a 95% yield: colorless oil; $R_f = 0.3$ (4:1 petroleum ether/EtOAc); IR (film) ν_{max} 2978, 1734, 1450, 1373, 1181; ¹H NMR (400 MHz, CDCl₃) δ 1.17–1.23 (m, 6H), 1.71–1.79 (m, 3H), 1.82–1.91 (m, 2H), 2.00–2.07 (m, 1H), 2.23–2.41 (m, 4H), 2.61–2.68 (m, 1H), 3.07–3.14 (m, 2H), 4.03–4.14 (m, 4H); ¹³C NMR (100 MHz, CDCl₃) δ 14.0, 14.1, 23.1, 23.8, 29.1, 32.0, 53.2, 53.9, 60.0, 60.3, 65.9, 173.4, 174.1.

Ethyl 2-Allyl-1-(4-ethoxy-4-oxobutyl)pyrrolidine-2-carboxylate (18). Compound 18 was prepared by a procedure analogous to that of compound 12 and gave a 94% yield: $R_f = 0.5$ (3:1 petroleum ether/EtOAc); IR (film) ν_{max} 2978, 1730, 1449, 1179, 1028, 916; ¹H NMR (400 MHz, CDCl₃) δ 1.21–1.26 (m, 6H), 1.71–1.85 (m, SH), 2.04–2.08 (m, 1H), 2.19–2.34 (m, 4H), 2.51–2.59 (m, 2H), 2.63– 2.70 (m, 1H), 3.07–3.12 (m, 1H), 4.07–4.13 (m, 4H), 5.01–5.07 (m, 2H), 5.71–5.80 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 14.2, 14.4, 21.7, 24.2, 31.9, 33.6, 39.2, 48.0, 51.0, 59.9, 60.1, 70.0, 117.5, 134.4, 173.7, 174.0; HRMS (ESI) *m*/*z* calcd for C₁₆H₂₈NO₄ 298.2013, found for [M + H]⁺ 298.2007.

Ethyl 8a-Allyl-8-hydroxy-1,2,3,5,6,8a-hexahydroindolizine-7-carboxylate (19). Compound 19 was prepared by a procedure analogous to that of compound 13 and gave a 75% yield: $R_f = 0.35$ (3:1 petroleum ether/EtOAc); IR (film) ν_{max} 2936, 1651, 1611, 1222, 1038; ¹H NMR (400 MHz, CDCl₃) δ 1.29 (t, 3H, J = 7.0 Hz), 1.64–1.73 (m, 2H), 1.87–1.93 (m, 1H), 1.98–2.04 (m, 1H), 2.09 (ddd, 1H, J = 2.4, 5.6, 15.2 Hz), 2.37–2.54 (m, 3H), 2.77 (q, 1H, J = 8.8 Hz), 2.86–2.92 (m, 2H), 2.97–3.04 (m, 1H), 4.19 (q, 2H, J = 7.2 Hz), 5.03–5.10 (m, 2H), 5.81–5.90 (m, 1H), 12.33 (s, 1H, OH); ¹³C NMR (100 MHz, CDCl₃) δ 14.2, 17.7, 22.6, 34.2, 41.9, 41.9, 50.6, 60.4, 64.8, 95.3, 117.0, 134.6, 172.3, 175.5; HRMS (ESI) *m/z* calcd for C₁₄H₂₂NO₃ 252.1594, found for [M + H]⁺ 252.1594.

Ethyl 8a-Allyl-7-bromo-8-oxooctahydroindolizine-7-carboxylate (20). NBS (187 mg, 1.05 mmol) was added to a solution of compound 19 (251 mg, 1.00 mmol) in DMSO (5 mL). After the mixture was stirred at room temperature for 1 h, 20 mL of EtOAc was added. The mixture was washed with water $(3 \times 10 \text{ mL})$ and brine and dried over anhydrous Na2SO4. After evaporation of the solvent, the residue was purified by silica gel column chromatography eluting with 10:1 petroleum ether/EtOAc to give 20 as a yellowish oil (314 mg, 95% yield). Compound **20**: $R_f = 0.4$ (5:1 petroleum ether/EtOAc); IR (film) $\nu_{\rm max}$ 1759, 1731, 1445, 1283, 1228; ¹H NMR (400 MHz, $CDCl_3$) δ 1.23 (t, 3H, J = 7.2 Hz), 1.67–1.80 (m, 2H), 1.93–1.99 (m, 2H), 2.25-2.31 (m, 1H), 2.31-2.46 (m, 2H), 2.72-2.78 (m, 1H), 2.84-2.90 (m, 1H), 3.03-3.14 (m, 3H), 4.12-4.24 (m, 2H), 5.05-5.10 (m, 2H), 5.76–5.86 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 13.7, 21.8, 33.2, 34.2, 38.4, 40.9, 49.6, 62.2, 66.6, 72.2, 118.6, 133.2, 165.9, 201.8; HRMS (ESI) *m/z* calcd for C₁₄H₂₁BrNO₃ 330.0699, found for $[M + H]^+$ 330.0694.

Ethyl 11-Oxooctahydro-1H-7,10a-methanopyrrolo[1,2-a]azocine-7-carboxylate (21). A solution of AIBN (10 mg) in 1 mL of anhydrous benzene was added to a solution of 20 (329 mg, 1.00 mmol) in anhydrous benzene (30 mL) under a nitrogen atmosphere. The reaction mixture was brought to reflux. A solution of n-Bu₃SnH (0.29 mL, 1.10 mmol) in 15 mL of anhydrous benzene was slowly added over 1 h via a syringe pump. After refluxing for 4 h, the reaction mixture was cooled to rt and extracted with 1 N HCl $(3 \times 10 \text{ mL})$. The combined aqueous extracts were adjusted to pH 9-10 with saturated aqueous Na_2CO_3 and extracted with $CHCl_3$ (3 × 30 mL). The combined organic layers were washed with water and brine, dried, and evaporated under reduced pressure. The residue was purified by silica gel column chromatography eluting with 6:1 petroleum ether/ EtOAc to give compound 21 as a colorless oil (125 mg, 50% yield). Compound 21: $R_f = 0.2$ (1:2 petroleum ether/EtOAc); IR (film) ν_{max} 2957, 1736, 1722, 1454, 1285, 1113, 1024; ¹H NMR (400 MHz, $CDCl_3$) δ 1.29 (t, 3H, J = 7.0 Hz), 1.36–1.41 (m, 1H), 1.49–1.59 (m, 2H), 1.67-1.75 (m, 2H), 1.94-2.02 (m, 2H), 2.17-2.37 (m, 5H), 2.48-2.54 (m, 1H), 2.68-2.73 (m, 1H), 3.11-3.16 (m, 1H), 3.20-3.24 (m, 1H), 4.22–4.27 (m, 2H); 13 C NMR (100 MHz, CDCl₃) δ 14.1, 17.5, 22.6, 31.9, 33.0, 37.8, 42.6, 49.4, 57.7, 57.5, 61.2, 71.7,

172.7, 211.8; HRMS (ESI) m/z calcd for C₁₄H₂₂NO₃ 252.1594, found for [M + H]⁺ 252.1588.

(3^{1} R,6 a^{5} ,9 a^{5})-Ethyl Decahydro-1H-pyrrolo[3,2,1-ij]quinoline-9a-carboxylate (22). Compound 22 was prepared by a procedure analogous to that of compound 16 and gave a 45% yield: R_{f} = 0.55 (10:1 CH₂Cl₂/CH₃OH); IR (film) ν_{max} 2931, 1725, 1457, 1166; ¹H NMR (400 MHz, C₆D₆) δ 0.97 (t, 3H, J = 7.0 Hz), 1.19– 1.26 (m, 2H), 1.41–1.58 (m, 3H), 1.59–1.86 (m, 6H), 1.96–2.03 (m, 2H), 2.10–2.17 (m, 2H), 2.53 (d, 1H, J = 3.2 Hz), 2.86–2.95 (m, 2H), 3.97–4.03 (m, 2H); ¹³C NMR (100 MHz, C₆D₆) δ 14.3, 21.4, 24.5, 25.9, 29.7, 33.0, 33.4, 35.1, 51.3, 52.9, 54.0, 60.1, 67.4, 175.8; HRMS (ESI) m/z calcd for C₁₄H₂₄NO₂ 238.1802, found for [M + H]⁺ 238.1798

(S)-Ethyl 1-(2-Ethoxy-2-oxoethyl)pyrrolidine-2-carboxylate (23).^{4d} Compound 23 was prepared by a procedure analogous to that of compound 11 and gave a 95% yield as a colorless oil: $R_f = 0.30$ (3:1 petroleum ether/EtOAc); IR (film) ν_{max} 2979, 2943, 1735, 733; ¹H NMR (400 MHz, CDCl₃) δ 1.18–1.24 (m, 6H), 1.46–1.53 (m, 2H), 1.56–1.66 (m, 2H), 1.73–1.79 (m, 1H), 1.84–1.92 (m, 2H), 2.03–2.10 (m, 1H), 2.26–2.39 (m, 4H), 2.62–2.69 (m, 1H), 3.06–3.16 (m, 2H), 4.05–4.17 (m, 4H); ¹³C NMR (100 MHz, CDCl₃) δ 14.1, 14.1, 22.8, 23.0, 28.1, 29.2, 34.0, 53.4, 54.5, 60.1, 60.4, 66.1, 173.5, 174.2.

Ethyl 9-Oxooctahydro-1H-pyrrolo[1,2-a]azepine-8-carboxylate (24). Sodium ethoxide was prepared from sodium (1.40 g, 61.00 mmol) and anhydrous EtOH (20 mL) in a 500 mL flask fitted with distillation equipment. Anhydrous xylene (200 mL) and compound 23 (15.00 g, 55.40 mmol) dissolved in 20 mL of dry xylene were successively added to the sodium ethoxide solution. The bath temperature was raised periodically, and the reaction mixture was distilled until no ethanol was detected in the distillate. The resulting residue was cooled to room temperature, and 60 mL of H2O was added to the flask. The mixture was extracted with ethyl acetate $(3 \times$ 100 mL), and the combined organic extracts were washed with water and brine and dried over anhydrous Na2SO4. The solvent was evaporated under reduced pressure, and the resulting residue was purified by silica gel column chromatography eluting with 2:1 petroleum ether/EtOAc to give a mixture of diastereoisomers as a yellowish oil (9.50 g, 76% yield) that could not be separated (2.5:1) chromatographically. Compound 24: $R_f = 0.50 (15:1 \text{ CH}_2\text{Cl}_2/\text{CH}_2)$ MeOH); IR (film) v_{max} 2937, 1742, 1711, 1304, 1187, 1110; major product ¹H NMR (400 MHz, CDCl₃) δ 1.24-1.28 (m, 3H), 1.70-1.89 (m, 5H), 1.95–2.15 (m, 4H), 2.33–2.49 (m, 3H), 2.99–3.04 (m, 2H), 3.11-3.17 (m, 2H), 4.09-4.22 (m, 3H); ¹³C NMR (100 MHz, CDCl₃) *δ* 14.0, 22.5, 25.9, 28.4, 28.7, 54.6, 55.5, 56.0, 60.8, 72.4, 171.3, 209.3; HRMS (ESI) m/z calcd for C₁₂H₂₀NO₃ 226.1438, found for [M + H]⁺ 226.1443.

Ethyl 9a-Allyl-9-oxooctahydro-1H-pyrrolo[1,2-a]azepine-8carboxylate (25). Allyl bromide (2.38 mL, 27.1 mmol) was added to a solution of compound 24 (6.1 g, 27.1 mmol) in anhydrous CH₃CN (40 mL). The mixture was stirred at room temperature for 6 days. The solid residue was separated by filtration and then dissolved in 40 mL of anhydrous CH₃CN, to which anhydrous potassium carbonate (4.00 g, 29.30 mmol) was added. The resulting slurry was brought to reflux for 1.5 h. The reaction mixture was cooled to room temperature and filtered, and the filtrate was concentrated and purified by silica gel column chromatography eluting with 4:1 petroleum ether/ EtOAc to give 25 as yellowish solids (4.31 g, 60% yield): $R_f = 0.60$ (EtOAc); IR (film) $\nu_{\rm max}$ 2937, 2803, 1742, 1711, 1450, 1369, 1304, 1187, 1110, 1030; ¹H NMR (400 MHz, CDCl₃) δ 1.24 (t, 3H, J = 7.2 Hz), 1.47-1.50 (m, 1H), 1.51-1.65 (m, 1H), 1.84-1.92 (m, 4H), 1.96–2.08 (m, 2H), 2.30 (dd, 1H, J = 6.4, 6.4 Hz), 2.45 (dd, 1H, J = 8.0, 8.0 Hz), 2.74-2.81 (m, 1H), 2.92-2.97 (m, 1H), 3.13-3.17 (m, 1H), 3.24–3.28 (m, 1H), 3.89 (dd, 1H, J = 4.0, 3.6 Hz), 4.17 (q, 2H, J = 7.2 Hz), 5.03–5.11 (m, 2H), 5.88–5.92 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 14.0, 23.4, 23.7, 24.2, 26.4, 34.4, 37.6, 46.3, 51.1, 54.3, 60.8, 117.2, 135.2, 171.1, 210.7; HRMS (ESI) m/z calcd for $C_{15}H_{24}NO_3$ 266.1751, found for $[M + H]^+$ 266.1756.

(8R,11S,11aR)-Ethyl 11-Acetoxy-12-oxodecahydro-8,11amethanopyrrolo[1,2-a]azonine-8-carboxylate (26a) and (8R,11R,11aR)-Ethyl 11-Acetoxy-12-oxodecahydro-8,11amethanopyrrolo[1,2-a]azonine-8-carboxylate (26b). DBU (0.64 mL, 4.20 mmol) under a nitrogen atmosphere was added to a solution of 24 (450 mg, 2.00 mmol) in anhydrous CH₃CN (30 mL). The reaction mixture was then brought to reflux. A solution of acrolein (134 mg, 2.40 mmol) in 2 mL of anhydrous CH₃CN was slowly added over 1 h via syringe pump. After the mixture had been refluxed for 4 h, Ac₂O (510 mg, 5.00 mmol) was added to the reaction mixture, and refluxing was continued for 4 h. Then the reaction mixture was cooled and stirred at room temperature for 5 h. The solvent was evaporated under reduced pressure, and the residue was dissolved in EtOAc (30 mL), washed with water $(3 \times 10 \text{ mL})$ and brine, and dried over anhydrous Na₂SO₄. The solvent was again evaporated under reduced pressure, and the residue was purified by silica gel column chromatography eluting with 2:1 petroleum ether/EtOAc to give 26a as a yellowish solid (357 mg, 55% yield) and 26b as a yellowish oil (65 mg, 10% yield). Compound **26a**: Mp 72 °C; $R_f = 0.65$ (EtOAc); IR (film) ν_{max} 2936, 1737, 1239, 1028; ¹H NMR (400 MHz, CDCl₃) δ 1.20 (t, 3H, J = 7.2 Hz), 1.49 (dd, 1H, J = 13.2, 5.6 Hz), 1.58–1.76 (m, 4H), 1.84-1.96 (m, 3H), 1.99 (s, 4H), 2.28-2.44 (m, 3H), 2.54-2.70 (m, 2H), 2.86 (dd, 1H, J = 13.6, 6.0 Hz), 3.10 (t, 1H, J = 7.6 Hz), 4.04–4.16 (m, 2H), 4.89 (d, 1H, J = 3.2 Hz); ¹³C NMR (100 MHz, CDCl₃) δ 13.9, 20.8, 22.3, 22.9, 25.1, 29.2, 29.3, 36.8, 54.3, 58.1, 59.7, 60.9, 73.7, 76.5, 169.9, 173.3, 207.0; HRMS (ESI) m/z calcd for C₁₇H₂₆NO₅ 324.1805, found for [M + H]⁺ 324.1812. X-ray crystallographic data of 26a: C17H25NO5, monoclinic, space group C_2/c , a = 30.456(6) Å, b = 8.4737(17) Å, c = 13.944(3) Å, $\beta =$ 106.162(2)°, Z = 8, $d_{\text{calcd}} = 1.243 \text{ g/cm}^3$, $R_1(I > 2\sigma(I)) = 0.0748$, wR_2 = 0.1888. Compound 26b: R_f = 0.5 (EtOAc); IR (film) ν_{max} 2936, 2812, 1738, 1707, 1455, 1370, 1245, 1037; ¹H NMR (400 MHz, $CDCl_3$) δ 1.26 (t, 3H, J = 7.2 Hz), 1.57–1.61 (m, 1H), 1.77–1.87 (m, 3H), 1.89-1.93 (m, 2H), 1.98-2.10 (m, 3H), 2.15 (s, 3H), 2.36-2.50 (m, 3H), 2.55-2.61 (m, 1H), 2.66-2.72 (m, 1H), 3.12 (dd, 1H, J = 13.2, 6.4 Hz), 3.22-3.23 (m, 1H), 4.15-4.21 (m, 2H), 4.89 (dd, 1H, J = 11.6, 4.4 Hz); ¹³C NMR (100 MHz, CDCl₃) δ 14.0, 21.3, 24.3, 24.9, 25.2, 29.6, 32.8, 36.5, 54.6, 58.9, 59.7, 61.4, 75.6, 77.3, 170.4, 173.0, 205.2; HRMS (ESI) m/z calcd for C₁₇H₂₆NO₅ 324.1805, found for [M + H]+ 324.1799.

(4¹R,7aS)-Ethyl 1,2,3,4¹,5,6,7,7a,8,9-Decahydropyrido[3,2,1ij]quinoline-7a-carboxylate (27a) and (4¹S,7aS)-Ethyl 1,2,3,4¹,5,6,7,7a,8,9-Decahydropyrido[3,2,1-ij]quinoline-7acarboxylate (27b). Zn dust (650 mg, 10.00 mmol) was added to the anhydrous HOAc (10 mL) solution of 26a or 26b (323 mg, 1.00 mmol). After the reaction mixture was stirred at room temperature for 24 h, it was filtered, and the HOAc was evaporated under reduced pressure. The resulting residue was adjusted to pH 9-10 with saturated aqueous Na_2CO_3 and extracted with $CHCl_3$ (3 × 30 mL). The combined organic layers were washed with water and brine, dried, and evaporated under reduced pressure. The residue was purified by silica gel column chromatography eluting with 40:1 CH₂Cl₂/CH₃OH to give 27a as a colorless oil (162 mg, 65% yield) and 27b as a yellowish oil (61 mg, 25% yield). Compound 27a: $R_f = 0.40$ (10:1 CH₂Cl₂/MeOH); IR (film) ν_{max} 2935, 1728, 1244, 1164, 1110; ¹H NMR (400 MHz, C_6D_6) δ 0.94 (t, 3H, J = 7.2 Hz), 1.31 (s, 1H), 1.45-1.48 (m, 1H), 1.60-1.73 (m, 3H), 1.74-1.80 (m, 2H), 1.90 (t, 1H, J = 10.0 Hz), 1.97–2.25 (m, 6H), 2.56–2.58 (m, 1H), 2.75 (dt, 1H, J = 4.4, 1.6 Hz), 3.07 (s, 1H), 3.92–4.00 (m, 2H), 5.36 (d, 1H, J = 5.2 Hz); ¹³C NMR (100 MHz, C_6D_6) δ 14.6, 22.2, 24.4, 26.6, 28.6, 35.0, 36.1, 45.7, 55.8, 58.3, 60.4, 64.1, 119.4, 138.9, 176.1; HRMS (ESI) m/z calcd for $C_{15}H_{24}NO_2$ 250.1802, found for $[M + H]^+$ 250.1799. Compound 27b: $R_f = 0.30 (10:1 \text{ CH}_2\text{Cl}_2/\text{MeOH})$; IR (film) $\nu_{\rm max}$ 2933, 1745, 1710, 1443, 1213, 1140; ¹H NMR (400 MHz, C_6D_6) δ 1.00 (t, 3H, J = 7.2 Hz), 1.36–1.47 (m, 3H), 1.79–1.87 (m, 3H), 1.89-1.96 (m, 4H), 2.01-2.10 (m, 2H), 2.29-2.39 (m, 3H), 2.74-2.77 (m, 2H), 3.98-4.10 (m, 2H), 5.22 (s, 1H); ¹³C NMR (100 MHz, C_6D_6) δ 14.3, 23.3, 23.8, 24.5, 33.0, 33.5, 36.8, 47.6, 55.9, 57.9, 60.0, 68.5, 119.3, 134.5, 173.2; HRMS (ESI) *m*/*z* calcd for C₁₅H₂₄NO₂ 250.1802, found for $[M + H]^+$ 250.1802.

(4¹S,7aR,10S,10aR)-Ethyl 10,10a-Dihydroxydodecahydropyrido[3,2,1-ij]quinoline-7a-carboxylate (28). A catalytic

amount of OsO4 (dissolved in 1 mL of i-PrOH) at room temperature was added to an acetone (20 mL) solution of 27a (950 mg, 3.80 mmol) and N-methylmorpholine N-oxide (NMO) (1.34 g, 11.40 mmol). After the mixture had been stirred for 24 h at room temperature, the reaction was quenched by the addition of saturated aqueous sodium sulfite solution (5 mL). The mixture was extracted with CHCl₃ (3×30 mL), and the combined organic extracts were washed with water and brine and dried over anhydrous Na2SO4. The solvent was evaporated under reduced pressure, and the resulting residue was purified by silica gel column chromatography eluting with 20:1 CH₂Cl₂/MeOH to give 28 as white crystals (750 mg, 70% yield). Compound 28: Mp 136 °C; $R_f = 0.30$ (10:1 CH₂Cl₂/MeOH); IR (film) $\nu_{\rm max}$ 3441, 2936, 1726, 1445, 1247, 1168, 1131, 1041; ¹H NMR (400 MHz, CDCl₃) δ 1.08–1.17 (m, 1H), 1.24 (t, 3H, J = 7.2 Hz), 1.41-1.55 (m, 3H), 1.64-1.79 (m, 6H), 1.92-2.07 (m, 5H), 2.28 (d, 1H, J = 12.8 Hz), 2.55 (s, 1H), 2.80 (d, 2H, J = 11.2 Hz), 4.02-4.10 (m, 2H), 4.13–4.22 (m, 1H); 13 C NMR (100 MHz, CDCl₃) δ 14.0, 20.4, 21.8, 25.3, 27.9, 34.9, 35.4, 44.2, 56.6, 57.5, 60.3, 67.6, 71.1, 72.6, 177.3; HRMS (ESI) m/z calcd for C₁₅H₂₆NO₄ 284.1856, found for [M + H]⁺ 284.1857. X-ray crystallographic data of 28: C₁₅H₂₅NO₄, triclinic, space group $P\overline{1}$, a = 8.410(5) Å, b = 8.707(6) Å, c = 10.620(7)Å, $\alpha = 101.173(6)^{\circ}$, $\beta = 103.851(6)^{\circ}$, $\gamma = 90.396(6)^{\circ}$, Z = 2, $d_{calcd} =$ 1.272 g/cm^3 , $R_1(I > 2\sigma(I)) = 0.0462$, $wR_2 = 0.1094$.

(4¹R, 7aR, 10aS)-Decahydro-7a, 10a-(epoxymethano)pyrido-[3,2,1-ij]quinolin-11-one (29). Compound 27b (249 mg, 1.00 mmol) was dissolved in 10 mL of HCl (4 N), and the mixture was brought to reflux for 24 h. The reaction mixture was cooled, adjusted to pH 9–10 with Na₂CO₃, and extracted with CHCl₃ (3×15 mL). The combined organic layers were washed with water and brine, dried, and evaporated under reduced pressure. The residue was purified by silica gel column chromatography eluting with 40:1 CH₂Cl₂/CH₃OH to give 29 as white crystals (145 mg, 65% yield). Compound 29: Mp 80 °C; $R_f = 0.70$ (10:1 CH₂Cl₂/MeOH); IR (film) ν_{max} 2931, 1770, 1441, 1119, 926; ¹H NMR (400 MHz, CDCl₃) δ 1.20–1.29 (m, 1H), 1.36-1.51 (m, 5H), 1.60-1.75 (m, 4H), 1.80-1.96 (m, 2H), 2.04 (d, 2H, J = 4.4 Hz), 2.14–2.26 (m, 3H), 2.64 (dd, 2H, J = 11.2, 1.6 Hz); ^{13}C NMR (100 MHz, CDCl₃) δ 18.7, 21.6, 23.3, 28.4, 31.1, 32.3, 34.0, 49.6, 52.6, 52.7, 72.8, 80.5, 179.4; HRMS (ESI) m/z calcd for $C_{13}H_{20}NO_2$ 222.1489, found for $[M + H]^+$ 222.1492.

(4¹R,7aR,10S,10aS)-Ethyl 10-Hydroxydodecahydropyrido-[3,2,1-ij]quinoline-7a-carboxylate (30). BH₃ (1 M in THF, 3 mL, 3.00 mmol) was added to an anhydrous THF (10 mL) solution of compound 27a (498 mg, 2.00 mmol) under a nitrogen atmosphere. The reaction mixture was brought to reflux. After refluxing for 12 h, the reaction mixture was cooled to room temperature, and KOH (4 mL, 3 M) and H₂O₂ (50%, 0.19 mL) were added to the flask. After the mixture was stirred at room temperature for 0.5 h, the organics were extracted with ethyl acetate $(3 \times 20 \text{ mL})$, and the combined organic extracts were washed with water and brine and dried over anhydrous Na₂SO₄. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography eluting with 30:1 CH₂Cl₂/CH₃OH to give 27 as white crystals (375 mg, 70% yield). Compound **30**: Mp 123 °C; $R_f = 0.35$ (10:1 CH₂Cl₂/MeOH); IR (film) ν_{max} 3360, 2939, 1725, 1445, 1250, 1191, 1127, 1031; ¹H NMR (400 MHz, CDCl₃) δ 1.24 (t, 3H, J = 7.2 Hz), 1.29–1.38 (m, 2H), 1.39-1.48 (m, 2H), 1.53-1.60 (m, 3H), 1.67-1.70 (m, 1H), 1.78-1.93 (m, 4H), 1.96-2.06 (m, 2H), 2.10-2.17 (m, 2H), 2.58 (s, 1H), 2.75 (d, 1H, J = 10.4 Hz), 2.86 (d, 1H, J = 10.4 Hz), 4.05 (td, 1H, J = 11.2, 4.8 Hz), 4.12–4.20 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 14.1, 20.6, 20.7, 25.0, 26.1, 33.5, 34.9, 41.4, 47.4, 57.1, 58.1, 60.4, 66.0, 66.5, 176.3; HRMS (ESI) m/z calcd for C₁₅H₂₆NO₃ 268.1907, found for [M + H]⁺ 268.1901. X-ray crystallographic data of **30**: $C_{15}H_{25}NO_3$, monoclinic, space group P2(1)/c, a = 8.186(16) Å, b = 23.09(5) Å, c = 8.398(17) Å, $\beta = 118.853(18)^{\circ}$, Z = 4, $d_{calcd} =$ 1.277 g/cm³, $R_1(I > 2\sigma(I)) = 0.0813$, $wR_2 = 0.2102$.

(4¹R,7aR,10aS)-Ethyl 10-Oxododecahydropyrido[3,2,1-ij]quinoline-7a-carboxylate (31). DMSO (273 mg, 3.50 mmol) at -78 °C was added to an anhydrous solution of CH₂Cl₂ (5 mL) and (COCl)₂ (0.17 mL, 1.75 mmol) under a nitrogen atmosphere. Compound 30 (390 mg, 1.46 mmol) was added to the flask after the mixture had been stirred at -78 °C for 15 min. The reaction mixture was stirred at -78 °C for another 1.5 h before Et₂N (1.0 mL) was added. The mixture was slowly warmed to room temperature over the course of 1 h, diluted with 20 mL of CH2Cl2, washed with water and brine, dried, and evaporated under reduced pressure. The residue was purified by silica gel column chromatography eluting with 40:1 CH₂Cl₂/CH₃OH to give compound 31 as a colorless oil (320 mg, 85% yield). Compound 31: $R_f = 0.40$ (10:1 CH₂Cl₂/MeOH); IR (film) $\nu_{\rm max}$ 2944, 1719, 1444, 1250, 1125, 1027; ¹H NMR (400 MHz, $CDCl_3$) δ 1.14–1.21 (m, 1H), 1.30 (t, 3H, J = 7.2 Hz), 1.42 (d, 1H, J = 13.6 Hz), 1.49-1.53 (m, 1H), 1.69-1.96 (m, 4H), 1.99-2.10 (m, 3H), 2.28 (dd, 1H, J = 13.2, 2.0 Hz), 2.36-2.46 (m, 2H), 2.51-2.58 (m, 2H), 2.77-2.82 (m, 2H), 2.85 (d, 1H, J = 1.6 Hz), 4.20-4.28 (m, 2H), 2.77-2.82 (m, 2H), 2.85 (d, 1H, J = 1.6 Hz), 4.20-4.28 (m, 2H), 2.85 (d, 1H, J = 1.6 Hz), 4.20-4.28 (m, 2H), 2.85 (d, 2H),2H); 13 C NMR (100 MHz, CDCl₃) δ 14.2, 20.5, 21.6, 23.8, 26.7, 34.3, 38.5, 46.0, 47.2, 57.1, 57.7, 60.8, 67.7, 175.8, 209.9; HRMS (ESI) m/z calcd for $C_{15}H_{24}NO_3$ 266.1751, found for $[M + H]^+$ 266.1755.

Ethyl 10-Oxo-1,2,3,5,6,7,7a,8,9,10-decahydropyrido[3,2,1ij]quinoline-7a-carboxylate (32). m-CPBA (70%, 95 mg, 0.39 mmol) at 0 °C was added to a solution of 31 (93 mg, 0.35 mmol) in 5 mL of CH₂Cl₂. The resulting mixture was stirred at 0 °C for 0.5 h and then stirred at room temperature for 3 h. After addition of 1 mL of saturated aqueous NaHCO₃, the reaction mixture was stirred for 5 min and extracted with CHCl₃. The combined organic layers were washed with water and brine, dried over Na2SO4, and evaporated under reduced pressure to give the corresponding N-oxide. The N-oxide was then taken up in 5 mL of anhydrous CH₂Cl₂ and stirred under a nitrogen atmosphere at 0 °C. Trifluoroacetic anhydride (TFAA, 0.25 mL) was added dropwise over the course of 5 min, and the resulting reaction mixture was allowed to stir for 1 h at 0 $^\circ$ C. The reaction mixture was concentrated in vacuo, diluted with CH₂Cl₂ (15 mL), treated with saturated aqueous Na2CO3 (5 mL), and stirred for 10 min. The layers were separated, and the organic layer was washed with water and brine, dried, and evaporated under reduced pressure. The residue was purified by silica gel column chromatography eluting with 50:1 CH₂Cl₂/CH₃OH to give 32 as a yellow oil (60 mg, 65% yield). Compound 31: $R_f = 0.40$ (20:1 CH₂Cl₂/MeOH); IR (film) ν_{max} 2942, 1725, 1554, 1290, 1190; ¹H NMR (400 MHz, $CDCl_3$) δ 1.25 (t, 3H, J = 7.2 Hz), 1.56 (td, 1H, J = 13.2, 4.4 Hz), 1.71-1.90 (m, 5H), 2.14-2.38 (m, 5H), 2.60-2.67 (m, 1H), 3.10-3.16 (m, 1H), 3.20-3.25 (m, 3H), 4.15–4.23 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 14.1, 19.9, 19.9, 20.1, 32.2, 33.6, 33.7, 47.1, 50.2, 51.1, 61.4, 106.6, 157.6, 173.3, 192.7; HRMS (ESI) *m*/*z* calcd for C₁₅H₂₂NO₃ 264.1594, found for M + H]⁺ 264.1588.

2,3,5,6,7,9,10,10a-Octahydropyrido[3,2,1-ij]quinolin-8(1H)one (33). CaCl₂ (152 mg, 1.36 mmol) was added to a solution of 32 (45 mg, 0.17 mmol) in 5 mL of DMSO. The mixture was heated at 170 °C for 6 h under a nitrogen atmosphere, cooled to rt, and diluted with 20 mL of CH₂Cl₂. The resulting mixture was washed with water $(5 \times 10 \text{ mL})$ and brine, dried, and evaporated under reduced pressure. The residue was purified by silica gel column chromatography eluting with 40:1 CH₂Cl₂/CH₃OH to give 33 as a yellow oil (26 mg, 80% yield). Compound 33: $R_f = 0.35$ (10:1 CH₂Cl₂/MeOH); IR (film) $\nu_{\rm max}$ 2934, 1603, 1543, 1315, 1190; ¹H NMR (400 MHz, C₆D₆) δ 0.69-0.80 (m, 1H), 1.18-1.25 (m, 3H), 1.28-1.35 (m, 1H), 1.38-1.42 (m, 1H), 1.43–1.49 (m, 2H), 1.76 (t, 1H, J = 12 Hz), 2.15–2.24 (m, 1H), 2.38–2.43 (m, 2H), 2.45–2.48 (m, 3H), 2.57 (ddd, 1H, J = 6.4, 4.0, 2.4 Hz), 2.90 (dt, 1H, J = 16, 5.6 Hz); ¹³C NMR (100 MHz, C_6D_6 δ 20.5, 21.0, 23.2, 28.7, 29.9, 35.8, 37.4, 50.4, 50.6, 105.8, 158.4, 192.3; HRMS (ESI) m/z calcd for C₁₂H₁₈NO 192.1383, found for [M + H]⁺ 192.1380.

(7S,10S,10aR)-Ethyl 10-Acetoxy-11-oxooctahydro-1H-7,10amethanopyrrolo[1,2-a]azocine-7-carboxylate (36a) and (7S,10R,10aR)-Ethyl 10-Acetoxy-11-oxooctahydro-1H-7,10amethanopyrrolo[1,2-a]azocine-7-carboxylate (36b). A solution of compound 17 (6.80 g, 26.50 mmol) in dry THF (15 mL) at 0 °C was added to a stirring mixture of KO'Bu (3.60 g, 31.80 mmol) in 150 mL of dry THF. After 1 h, 10 mL of water was added to quench the reaction. Then the mixture was adjusted to pH 7 with 2 M HCl and extracted with ethyl acetate (50 mL). The aqueous layer was extracted with CHCl₃ (5 × 50 mL), and all the combined organic extracts were

washed with water and brine and dried over anhydrous Na₂SO₄. Then the solvent was evaporated under reduced pressure to give the crude compound 35 as a yellowish oil (4.9 g), which did not need purification. DBU (7.44 mL, 48.70 mmol) was added to the anhydrous CH₂CN (60 mL) solution of crude compound 35 (4.90 g, 23.20 mmol) under a nitrogen atmosphere. The reaction mixture was brought to reflux. A solution of acrolein (1.56 g, 27.80 mmol) in 10 mL of anhydrous CH₃CN was slowly added over the course of 1 h via syringe pump. After the mixture had been refluxed for 4 h, Ac₂O (6.80 g, 66.00 mmol) was added slowly, and the mixture continued refluxing for 1 h. The reaction mixture was cooled and stirred at room temperature for 4 h. The solvent was evaporated under reduced pressure. The residue was dissolved in EtOAc (60 mL), and the solution was washed with water $(3 \times 20 \text{ mL})$ and brine and dried over anhydrous Na2SO4. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography eluting with 4:1 petroleum ether/EtOAc to give 36a as a yellow solid (5.30 g, 65% yield) and 36b as a yellow oil (1.32 g, 16% yield). Compound 36a: Mp 71 °C; Rf = 0.60 (EtOAc); IR (film) ν_{max} 2951, 1784, 1455, 1371, 1235, 1117, 1025; ¹H NMR (400 MHz, $CDCl_3$) δ 1.31 (t, 3H, J = 7.2 Hz), 1.50–1.54 (m, 1H), 1.68– 1.86 (m, 4H), 2.03 (s, 3H), 2.04-2.10 (m, 1H), 2.23-2.27 (m, 1H), 2.35-2.64 (m, 4H), 2.71-2.76 (m, 1H), 3.04-3.08 (m, 1H), 3.20-3.22 (m, 1H), 4.26 (q, 2H, J = 7.2 Hz), 4.97 (q, 1H, J = 2.4 Hz); ¹³C NMR (100 MHz, CDCl₃) δ 14.0, 21.0, 21.7, 22.3, 27.4, 32.1, 33.0, 49.6, 56.9, 57.4, 61.3, 73.2, 79.2, 170.1, 172.2, 207.9; HRMS (ESI) m/z calcd for C₁₆H₂₄NO₅ 310.1649, found for [M + H]⁺ 310.1656. X-ray crystallographic data of 36a: C16H23NO5, monoclinic, space group P2(1)/c, a = 15.235(16) Å, b = 7.700(8) Å, c = 14.339(15) Å, $\beta =$ 108.123(11)°, Z = 4, d_{calcd} = 1.285 g/cm³, $R_1(I > 2\sigma(I))$ = 0.0491, wR_2 = 0.1167. Compound **36b**: R_f = 0.40 (EtOAc); IR (film) ν_{max} 2958, 2802, 1741, 1454, 1370, 1258, 1115, 1033; ¹H NMR (400 MHz, $CDCl_3$) δ 1.30 (t, 3H, J = 7.2 Hz), 1.55–1.60 (m, 1H), 1.68–1.77 (m, 2H), 1.88-2.09 (m, 2H), 2.10-2.14 (m, 4H), 2.19-2.26 (m, 2H), 2.34-2.41 (m, 2H), 2.57-2.64 (m, 1H), 2.71-2.76 (m, 1H), 3.14-3.18 (m, 1H), 3.27-3.31 (m, 1H), 4.20-4.28 (m, 2H), 4.64 (dd, 1H, J = 11.2, 4.8 Hz); ¹³C NMR (100 MHz, CDCl₃) δ 14.0, 21.0, 23.3, 23.3, 29.2, 29.9, 32.4, 49.4, 56.2, 58.1, 61.4, 75.7, 78.4, 169.9, 171.8, 206.7; HRMS (ESI) m/z calcd for C₁₆H₂₄NO₅ 310.1649, found for $[M + H]^+$ 310.1651.

(3¹R,9aS)-Ethyl 2,3¹,4,5,6,8,9,9a-Octahydro-1H-pyrrolo-[3,2,1-ij]quinoline-9a-carboxylate (37). Zn dust (1.30 g, 20.00 mmol) was added to the anhydrous HOAc (30 mL) solution of 36a or 36b (618 mg, 2.00 mmol). The reaction mixture was brought to reflux under a nitrogen atmosphere. After refluxing for 24 h, the reaction mixture was filtered, and HOAc was evaporated under reduced pressure. The residue was adjusted to pH 9-10 with saturated Na_2CO_3 and extracted with $CHCl_3$ (3 × 30 mL). The combined organic layers were washed with water and brine, dried, and evaporated under reduced pressure. The residue was purified by silica gel column chromatography eluting with 40:1 CH₂Cl₂/CH₃OH to give 37 as a colorless oil (273 mg, 58% yield). Compound 37: R_f = 0.40 (10:1 CH₂Cl₂/MeOH); IR (film) $\nu_{\rm max}$ 2937, 1724, 1454, 1223, 1173, 1091, 1026; ¹H NMR (400 MHz, C_6D_6) δ 0.94 (t, 3H, J = 7.2 Hz), 1.43-1.50 (m, 1H), 1.61-1.75 (m, 3H), 1.84-2.02 (m, 2H), 2.08-2.27 (m, 6H), 2.84 (t, 1H, J = 7.6 Hz), 2.89 (s, 1H), 2.95 (d, 1H, J = 10.8 Hz), 3.90–4.03 (m, 2H), 5.44 (d, 1H, J = 6.0 Hz); ¹³C NMR (100 MHz, C₆D₆) δ 14.2, 23.9, 27.5, 31.8, 33.2, 36.7, 49.9, 53.1, 53.8, 60.3, 67.1, 118.6, 136.5, 176.1; HRMS (ESI) *m/z* calcd for C₁₄H₂₂NO₂ 236.1645, found for [M + H]⁺ 236.1650.

 $(3^{1}R,6aS,9aS)$ -Ethyl Decahydro-1H-pyrrolo[3,2,1-ij]quinoline-9a-carboxylate (22). A flask containing 37 (50 mg, 0.21 mmol) and PtO₂ (10 mg) in 5 mL of MeOH was thoroughly purged with hydrogen and was then fitted with a hydrogen balloon. After the mixture was stirred for 72 h at room temperature, it was filtered. The filtrate was concentrated under reduced pressure and afforded 22 as a colorless oil (47 mg, 95% yield).

(3¹S,6aR,7S,9aS)-Ethyl 6a,7-Dihydroxydecahydro-1Hpyrrolo[3,2,1-ij]quinoline-9a-carboxylate (38). Compound 38 was prepared by a procedure analogous to that of compound 28 and gave a 65% yield: Mp 115 °C; $R_f = 0.30$ (10:1 CH₂Cl₂/MeOH); IR (film) ν_{max} 3354, 2937, 1725, 1448, 1214, 1027; ¹H NMR (400 MHz, CDCl₃) δ 1.13 (td, 1H, J = 13.6, 5.6 Hz), 1.29 (t, 3H, J = 7.2 Hz), 1.52–1.76 (m, 5H), 1.88–2.05 (m, 5H), 2.15–2.22 (m, 1H), 2.34–2.39 (m, 2H), 2.97 (d, 1H, J = 10.8 Hz), 3.08 (td, 1H, J = 9.2, 3.2 Hz), 3.85 (dd, 1H, J = 11.6, 4.8 Hz), 4.18–4.25 (m, 2H), 4.85 (brs, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 14.0, 22.8, 28.4, 32.9, 33.0, 33.4, 51.5, 51.6, 52.6, 61.5, 68.1, 70.6, 71.7, 178.6; HRMS (ESI) m/z calcd for C₁₄H₂₄NO₄ 270.1700, found for [M + H]⁺ 270.1703. X-ray crystallographic data of **38**: C₁₄H₂₃NO₄, monoclinic, space group P2(1)/c, a = 9.978(6) Å, b = 8.194(5) Å, c = 17.056(10) Å, $\beta = 95.767(7)^{\circ}$, Z = 4, $d_{calcd} = 1.289$ g/cm³, $R_1(I > 2\sigma(I)) = 0.0770$, $wR_2 = 0.1708$.

ASSOCIATED CONTENT

Supporting Information

Full experimental procedures, spectral data, copies of ¹H and ¹³C NMR spectra for compounds 11–25, 26a, 26b, 27a, 27b, 28–33, 36a, 36b, 37, and 38; X-ray crystallographic data for compounds 16, 26a, 28, 30, 36a, and 38; and CIF files for 16, 26a, 28, 30, 36a, and 38. This material is available free of charge via the Internet at http://pubs.acs.org.

AUTHOR INFORMATION

Corresponding Author

*E-mail: wdli@cqu.edu.cn. Phone: 0086-(0)23-65678459.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

We thank the National Natural Science Foundation (21132006) for financial support. The Cheung Kong Scholars program and the Scholars program of Chongqing University are gratefully acknowledged.

REFERENCES

(1) (a) Li, W.-D. Z.; Wang, Y.-Q. Org. Lett. **2003**, *5*, 2931; **2009**, *11*, 1865. (b) Ma, B.-C.; Wang, Y.-Q.; Li, W.-D. Z. J. Org. Chem. **2005**, *70*, 4528.

(2) (a) Clemo, G. R.; Ramage, G. R. J. Chem. Soc. 1931, 437.
(b) Clemo, G. R.; Raper, R.; Vipond, H. J. J. Chem. Soc. 1949, 2095.
(3) Prelog, V.; Seiwerth, R. Chem. Ber. 1939, 72, 1638.

(4) (a) Leonard, N. J.; Wildman, W. C. J. Am. Chem. Soc. 1949, 71, 3089. (b) Leonard, N. J.; Ruyle, W. V. J. Am. Chem. Soc. 1949, 71, 3094. (c) Leonard, N. J.; Barthel, E., Jr. J. Am. Chem. Soc. 1949, 71, 3098. (d) Leonard, N. J.; Wildman, W. C. J. Am. Chem. Soc. 1949, 71, 3100. (e) Leonard, N. J.; Barthel, E., Jr. J. Am. Chem. Soc. 1950, 72, 3632. (f) Leonard, N. J.; Pines, S. H. J. Am. Chem. Soc. 1950, 72, 4931. (g) Leonard, N. J.; Nicolaides, E. D. J. Am. Chem. Soc. 1951, 73, 5210. (h) Leonard, N. J.; Sentz, R. C. J. Am. Chem. Soc. 1952, 74, 1704. (i) Leonard, N. J.; Sentz, R. C.; Middleton, W. J. J. Am. Chem. Soc. 1953, 75, 1674. (j) Leonard, N. J.; Fuller, G.; Dryden, H. L., Jr. J. Am. Chem. Soc. 1953, 75, 3727. (k) Leonard, N. J.; Curry, J. W.; Sagura, J. J. J. Am. Chem. Soc. 1953, 75, 6249. For relevant mechanistic perspectives on the classic Clemmensen reductions, see: (1) Brewster, J. H. J. Am. Chem. Soc. 1954, 76, 6364. (m) Staschewski, D. Angew. Chem. 1959, 71, 726. (n) Nakabayash, T. J. Am. Chem. Soc. 1960, 82, 3900, 3906, 3909. (o) Di Vona, M. L.; Rosnati, V. J. Org. Chem. 1991, 56, 4269.

(5) For earlier syntheses of benzazepine derivatives via this type of reductive rearrangement, see: (a) Schöpf, C.; Schweickert, M. Chem. Ber. **1965**, 98, 2566. (b) Hazebroucq, G.; Pharm, C. H.; Paris, F. Ann. Chim. (Paris, Fr.) **1966**, 1, 221; See also: Chem. Abstr. **1967**, 2461. (c) Kametani, T.; Hirata, S.; Hibino, S.; Nemoto, H.; Ihara, M.; Fukomoto, K. Heterocycles **1975**, 3, 151 ; see also reference 1 therein.

(6) For recent reviews on the chemistry of Stemona alkaloids, see: (a) Pilli, R. A.; Ferreira de Oliveira, M. d. C. Nat. Prod. Rep. 2000, 17, 117. (b) Pilli, R. A.; Rosso, G. B.; Ferreira de Oliveira, M. d. C. In The Alkaloids: Chemistry and Biology; Cordell, G. A., Ed.; Academic Press: New York, 2005; Vol. 62, pp 77-173. For selected recent synthetic studies, see: (c) Rigby, J. H.; Laurent, S.; Cavezza, A.; Heeg, M. J. J. Org. Chem. 1998, 63, 5587. (d) Hinman, M. M.; Heathcock, C. H. J. Org. Chem. 2001, 66, 7751. (e) Padwa, A.; Ginn, J. D. J. Org. Chem. 2005, 70, 5197. (f) Frankowski, K. J.; Golden, J. E.; Zeng, Y.-B.; Yao, L.; Aubé, J. J. Am. Chem. Soc. 2008, 130, 6018. (g) Frankowski, K. J.; Neuenswander, B.; Aubé, J. J. Comb. Chem. 2008, 10, 721. (h) Tang, M.; Fan, C.-A.; Zhang, F.-M.; Tu, Y.-Q. Tetrahedron 2009, 65, 5716. (i) Chen, J.-B.; Chen, J.-C.; Xie, Y.; Zhang, H.-B. Angew. Chem., Int. Ed. 2012, 51, 1024 ; see also references therein..

(7) For a recent review on the chemistry of Aspidosperma alkaloids, see: (a) Saxton, J. E. In The Alkaloids: Chemistry and Biology; Cordell, G. A., Ed.; Academic Press: New York, 1998; Vol. 51, pp 1-197. For selected recent synthetic studies, see: (b) Iyengar, R.; Schildknegt, K.; Morton, M.; Aubé, J. J. Org. Chem. 2005, 70, 10645. (c) Ishikawa, H.; Elliott, G. I.; Velcicky, J.; Choi, Y.; Boger, D. L. J. Am. Chem. Soc. 2006, 128, 10596. (d) Sharp, L. A.; Zard, S. Z. Org. Lett. 2006, 8, 831. (e) Mejía-Oneto, J. M.; Padwa, A. Org. Lett. 2006, 8, 3275. (f) Coldham, I.; Burrel, A. J. M.; White, L. E.; Adams, H.; Oram, N. Angew. Chem., Int. Ed. 2007, 46, 6159. (g) Martin, D. B. C.; Vanderwal, C. D. J. Am. Chem. Soc. 2009, 131, 3472. (h) Sasaki, Y.; Kato, D.; Boger, D. L. J. Am. Chem. Soc. 2010, 132, 13533. (i) De Simone, F.; Gertsch, J.; Waser, J. Angew. Chem., Int. Ed. 2010, 49, 5767. (j) Tam, N. T.; Jung, E.-J.; Cho, C.-G. Org. Lett. 2010, 12, 2012. (k) Jones, S. B.; Simmons, B.; Mastracchio, A.; MacMillan, D. W. C. Nature 2011, 475, 183. (1) Jiao, L.; Herdtweck, E.; Bach, T. J. Am. Chem. Soc. 2012, 134, 14563. (m) Xie, J.; Wolfe, A. L.; Boger, D. L. Org. Lett. 2013, 15, 868 ; see also references therein.

(8) For recent reviews on the chemistry of Lycopodium alkaloids, see: (a) Ma, X.; Gang, D. R. Nat. Prod. Rep. 2004, 21, 752. (b) Kobayashi, J.; Morita, H. In The Alkaloids: Chemistry and Physiology; Cordell, G. A., Ed.; Academic Press: New York, 2005; Vol. 61, pp 1-57. (c) Hirasawa, Y.; Kobayashi, J.; Morita, H. Heterocycles 2009, 77, 679. For selected recent synthetic studies, see: (d) Evans, D. A.; Scheerer, J. R. Angew. Chem., Int. Ed. 2005, 44, 6038. (e) Yang, H.; Carter, R. G.; Zakharov, L. N. J. Am. Chem. Soc. 2008, 130, 9238. (f) Yang, H.; Carter, R. G. J. Org. Chem. 2010, 75, 4929. (g) Laemmerhold, K. M.; Breit, B. Angew. Chem., Int. Ed. 2010, 49, 2367. (h) Ramharter, J.; Weinstabl, H.; Mulzer, J. J. Am. Chem. Soc. 2010, 132, 14338. (i) Boonsompat, J.; Padwa, A. J. Org. Chem. 2011, 76, 2753. (j) Ge, H.-M.; Zhang, L.-D.; Tan, R.-X.; Yao, Z.-J. J. Am. Chem. Soc. 2012, 134, 12323. (k) Li, H.-H.; Wang, X.-M.; Hong, B.-K.; Lei, X.-G. J. Org. Chem. 2013, 78, 800. (1) Pigza, J. A.; Han, J.; Chandra, A.; Mutnick, D.; Pink, M.; Johnston, J. N. J. Org. Chem. 2013, 78, 822. (m) Saha, M.; Carter, R. G. Org. Lett. 2013, 15, 736 ; see also references therein. (9) (a) Leonard, N. J.; Swann, S., Jr.; Figueras, J., Jr. J. Am. Chem. Soc. 1953, 74, 4620. (b) Kunieda, T.; Koga, K.; Yamada, S. Chem. Pharm. Bull. 1967, 15, 337. (c) Barker, D.; Tong, S. T. Tetrahedron Lett. 2006, 47, 5017.

(10) For a recent review on the chemistry of $\mathsf{Mn}^{\mathrm{III}}\text{-}\mathsf{based}$ oxidative free-radical cyclization, see: Snider, B. B. Tetrahedron 2009, 65, 10738.

(11) For an interesting, unexpected tandem cyclization-rearrangement pathway leading to an analogous azepinoindole framework, see: Wang, Q.; Padwa, A. Org. Lett. 2006, 8, 601.

(12) Kuehne, M. E.; Bayha, C. Tetrahedron Lett. 1966, 12, 1311.

(13) Essentially racemic products were obtained throughout this report starting from L-proline derivatives 17 (Schemes 2 and 5) and 23 (Scheme 3). For racemization and relevant studies, see ref 9b.

(14) For recent reviews on the construction of bridged cyclic ring systems, see: (a) Presset, M.; Coquerel, Y.; Rodriguez, J. Chem. Rev. 2013, 113, 525. (b) Filippini, M. H.; Faure, R.; Rodriguez, J. Chem. Rev. 1999, 99, 27. For examples on the tandem Michael-Aldol annulation, see: (c) Filippini, M. H.; Faure, R.; Rodriguez, J. J. Org. Chem. 1965, 60, 6872. (d) Dauben, W. G.; Bunce, R. A. J. Org. Chem. 1983, 48, 4642. (e) Gambacorta, A.; Fabrizi, G.; Bovicelli, P.

Tetrahedron 1992, 48, 4459. (f) Ouvrard, N.; Ouvrard, P.; Rodriguez, J.; Santelli, M. J. Chem. Soc., Chem. Commun. 1993, 571. (g) Simon, C.; Peyronel, J. F.; Clerc, F.; Rodriguez, J. Eur. J. Org. Chem. 2002, 3359. (h) Vafina, G. F.; Yakhina, G. R.; Khakimova, T. V.; Spirikhin, L. V.; Galin, F. Z.; Yunusov, M. S. Russ. J. Org. Chem. 2003, 39, 49. (i) Nicolaou, K. C.; Carenzi, G. E. A.; Jeso, V. Angew. Chem., Int. Ed. 2005, 44, 3895. (j) Pradhan, T. K.; Hassner, A. Synlett 2007, 1071. (k) Ruiz, M.; López-Alvarado, P.; Menéndez, J. C. Org. Biomol. Chem. 2010, 8, 4521. (1) Huters, A. D.; Styduhar, E. D.; Garg, N. K. Angew. Chem., Int. Ed. 2012, 51, 3758.

(15) (a) Tsuda, Y.; Hosoi, S.; Ohshima, T.; Kaneuchi, S.; Murata, M.; Kiuchi, F.; Toda, J.; Sano, T. Chem. Pharm. Bull. 1985, 33, 3574. (b) Tsuda, Y.; Hosoi, S.; Nakai, A.; Sakai, Y.; Abe, T.; Ishi, Y.; Kiuchi, F.; Sano, T. Chem. Pharm. Bull. 1991, 39, 1365.

(16) (a) Valenta, Z.; Deslongchamps, P.; Ellison, R. A.; Wiesner, K. J. Am. Chem. Soc. 1964, 86, 2533. (b) Dugas, H.; Ellison, R. A.; Valenta, Z.; Wiesner, K.; Wong, C. M. Tetrahedron Lett. 1965, 18, 1279. (c) Wenkert, E.; Dave, K. G.; Stevens, R. V. J. Am. Chem. Soc. 1968, 90, 6177

(17) (a) Leonard, N. J.; Adamcik, J. A. J. Am. Chem. Soc. 1959, 81, 595. (b) Meyers, A. I.; Reine, A. H.; Gault, R. Tetrahedron Lett. 1967, 41, 4049. (c) Meyers, A. I.; Singh, S. Tetrahedron Lett. 1967, 52, 5319. (d) Meyers, A. I.; Reine, A. H.; Gault, R. J. Org. Chem. 1969, 34, 698. (e) Lin, H.-Y.; Snider, B. B. Org. Lett. 2011, 13, 1234. (f) Lin, H.-Y.; Causey, R.; Garcia, G. E.; Snider, B. B. J. Org. Chem. 2012, 77, 7143. (18) For detailed X-ray crystallographic and spectroscopic data of numbered compounds, see Supporting Information (SI-1 and SI-2).